Quick Answer
BeOne Medicines Ltd. reported Net Income Loss of $286.93 million for the year ending 2025.
- BeOne Medicines Ltd. showed an increase of +144.5% in Net Income Loss from 2024 to 2025.
- This data is from BeOne Medicines Ltd.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), BeOne Medicines Ltd.'s Net Income Loss has grown by 1,669.8%.
- Historical annual values: Fiscal year 2025: $286.93 million | Fiscal year 2024: -$644.79 million | Fiscal year 2023: -$881.71 million | Fiscal year 2022: -$2.00 billion | Fiscal year 2021: -$1.46 billion | Fiscal year 2020: -$1.62 billion | Fiscal year 2019: -$948.63 million | Fiscal year 2018: -$673.77 million | Fiscal year 2017: -$93.11 million | Fiscal year 2016: -$119.22 million | Fiscal year 2015: -$57.10 million | Fiscal year 2014: -$18.28 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: